Nano-Pharmceutical Company Enters Into Research Agreement with Vaccine Branch of National Cancer Institute
Nanotherapeutics, Inc. recently announced it has a two year Cooperative Research and Development Agreement (CRADA) with the Vaccine Branch of the National Cancer Institute (NCI). Nanotherapeutics plans to create HIV peptide oral vaccine nanoparticles using its exclusive technology. Mr. James D. Talton, Ph.D., Co-Founder and President of Nanotherapeutics, is the companyâ€™s principal investigator for the project. The collaboration with the NCI will involve the companyâ€™s proprietary nanoparticle delivery system to improve immune response.